SLC5A2 and Hypoglycemia: Tofogliflozin has the highest selectivity of all clinically developed inhibitors with 2900-fold greater selectivity for SGLT2 than SGLT1 [13], which may contribute to the relatively low incidence of adverse events including hypoglycemia, compared to that of other SGLT2 inhibitors [14].